



Novel Therapies and Biomarkers for Celiac Disease and Gluten-Related Disorders

Guest Editor:

Dr. Luca Elli

Center for Prevention and
Diagnosis of Coeliac Disease-
Gastroenterology and Endoscopy
Unit, Fondazione IRCCS Ca'
Granda Ospedale Maggiore
Policlinico, Via F. Sforza 35, 20122
Milan, Italy

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

Celiac Disease (CD) and the other gluten-related disorders (GRDs) are epidemiologically relevant phenomena with an approximate global prevalence near to 5%, involving different systems and metabolic pathways. Various mechanisms, both autoimmune and inflammatory, are implicated in the pathogenesis of GRDs and frequently share similar clinical manifestations, making their differential diagnosis challenging. They could involve different parts of the gastrointestinal tract, skin, and nervous and musculoskeletal systems, as they are systemic disorders. Among GRDs, CD is the most well-known, prevalent, and commonly studied.

In this Special Issue, we aim to expand our knowledge on all of the fundamental aspects of CD and other GRDs; therefore, this Special Issue will include new studies concerning the biological effect of gluten and new molecules as candidates for use in therapies, as novel therapeutic targets, biomarkers to diagnose GRDs and in monitoring the clinical responsiveness and, in general, new insights in the pathogenesis of GRD.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)